Repatha may help reduce the risk of heart attack, stroke, and heart surgery for adults with heart disease. It might also lower low-density lipoprotein (LDL) cholesterol in adults and children with ...
The FDA approved Amgen’s AMGN new cholesterol-lowering medication, Repatha (evolocumab), making it the second PCSK9 inhibitor to gain approval in the U.S. this year. Repatha’s approval comes a month ...
Following a price cut for its Repatha SureClick auto-injector in October, Amgen Inc. (AMGN) announced on Monday it is slashing the price of all Repatha devices by 60% to $5,850 per year. Repatha, one ...
Amgen announced that all Repatha (evolocumab) devices are now available at a 60% reduced list price. This includes the pre-filled syringe, the SureClick autoinjector, and the Pushtronex device, an ...
Amgen announced that as part of the company's commitment to improve patient affordability for an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback